Navigation Links
FDA Updates Prescription Guidelines for Blood Thinner
Date:8/18/2007

Gene variations dictate how quickly a patient metabolizes warfarin, officials say

THURSDAY, Aug. 16 (HealthDay News) -- The U.S. Food and Drug Administration announced Thursday a labeling update for the widely prescribed blood thinner warfarin (Coumadin), advising doctors that patients' genetic makeup can affect how they respond to the drug.

Responses to warfarin depend on a patient's variants of the genes CYP2C9 and VKORC1. About 30 percent of patients -- many of them heart patients -- who take warfarin have these gene variants.

These variations can determine how fast warfarin is metabolized, Larry Lesko, director of the FDA's office of clinical pharmacology at the Center for Drug Evaluation and Research, said during a teleconference. "Patients with these variations may need lower doses of warfarin than patients with the usual forms of these genes.

"The label change explains that certain people are likely to respond very differently to the drug if they happen to carry variations of two of their genes," Lesko said. The label updates are based on recent studies that found patients' response to the drug depends on these gene variations, he added.

In the United States, some 2 million people start taking warfarin every year to prevent blood clots, heart attacks and stroke, according to the FDA. Warfarin is tricky to use, because the correct dose varies and depends on risk factors, including diet, age, and other medications the patient is taking.

If the warfarin dose is too high, there is the risk of life-threatening bleeding. If the dose is too low, there is a risk of developing blood clots. Dosing is particularly important when starting the drug, the FDA said.

The FDA isn't mandating that doctors obtain genetic tests before prescribing warfarin but suggests that it is something doctors may want to consider when prescribing the drug.

"Doctors and other health-care professionals may well decide to incorporate genetic information along with more traditional risk factors in estimating their patient's warfarin doses," Lesko said. "It may improve the safe use of warfarin."

Lesko noted that genetic tests for the gene variants can cost $125 to $500. The tests may not be readily available in some parts of the United States, he said.

Dr. Janet Woodcock, the FDA's deputy commissioner and chief medical officer, noted during the teleconference that there isn't enough data to make genetic testing a mandate when prescribing warfarin.

"We have to test how good it will be to use genetic information versus the current methods, which are not perfectly satisfactory, but work to initiate warfarin therapy. Then we will have an answer to that question," Woodcock said.

Warfarin is the second most common drug to blame for emergency room visits for adverse drug events, after insulin, the FDA said.

Currently, patients need to have several blood tests over several weeks to determine their optimal warfarin dose.

Patients taking warfarin need to have their blood checked monthly to see if the drug is working properly. The test is called the PT -- or prothrombin time -- test, which evaluates the blood's ability to clot. The results are measured in seconds and compared with the expected value in healthy people.

The changes to the label will be made by manufacturers of warfarin, the generic version of Coumadin. Bristol-Myers Squibb Co., of Princeton, N.J., is the manufacturer of Coumadin, the FDA said.

More information

For more on warfarin, visit the U.S. National Library of Medicine.



SOURCES: Aug. 16, 2007, teleconference with Janet Woodcock, M.D., deputy commissioner and chief medical officer, U.S. Food and Drug Administration; Larry Lesko, Ph.D., director, office of clinical pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration


'/>"/>

Copyright©2007 ScoutNews,LLC.

Related medicine news :

1. WHO Updates Outdated Pediatric Growth Charts
2. A prescription cream for unwanted facial hair
3. Lose Weight With New Wonder Slimming FDA approved Prescription Drug
4. Prescription Drug - Helps People Stop Smoking
5. Misleading Advertisements for Prescription Drugs
6. Patients Pressure Would Result In Overprescription
7. TV drug commercials prompt prescriptions
8. Prescription Drug Use Varies Widely Between States
9. Status of some prescription drugs
10. Abuse of prescription drugs among youths on the rise
11. Does Your Prescription Have An Inappropriate Medicine?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... Mass. and SAN CLEMENTE, Calif. , ... California -based mobile pulmonary function testing company, is now able ... PFT devices developed by ndd Medical Technologies , Inc. ... testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® ... , can get any needed testing done in the comfort ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology: